1
|
Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 2015; 30:1440-3. [PMID: 26648537 DOI: 10.1038/leu.2015.333] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- M Gentile
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - T D Shanafelt
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - G Cutrona
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - S Molica
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - G Tripepi
- Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Reggio Calabria, Italy
| | - I Alvarez
- Division of Haematology, Dipartimento Oncologico e Tecnologie Avanzate, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy
| | - F R Mauro
- Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy
| | - N Di Renzo
- Hematology Unit, Ospedale Vito Fazzi, Lecce, Italy
| | - F Di Raimondo
- Division of Haematology, Department of Biomedical Sciences, University of Catania and Ferrarotto Hospital, Catania, Italy
| | - I Vincelli
- Hematology Unit, Dipartimento di Onco-Ematologia, A.O. of Reggio Calabria, Reggio Calabria, Italy
| | - K Todoerti
- Laboratory of Preclinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Dipartimento Onco-Ematologico, Potenza, Italy
| | - S Matis
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - C Musolino
- Division of Haematology, Dipartimento di Medicina Interna,University of Messina, Messina, Italy
| | - S Fabris
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - E Vigna
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - L Levato
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - S Zupo
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - F Angrilli
- Department of Hematology, Ospedale Santo Spirito, Pescara, Italy
| | - U Consoli
- U.O.S. di Emato-Oncologia, Ospedale Garibaldi-Nesima, Catania, Italy
| | - G Festini
- Dipartimento ad Attività Integrata Oncologia, Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy
| | - G Longo
- Dipartimento di Oncologia, Unità di Ematologia, Ospedale San Vincenzo, Taormina, Italy
| | - A Cortelezzi
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - A Arcari
- Dipartimento di Oncologia ed Ematologia, Hematology Unit, Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - M Federico
- Department of Onco-hematology, Università di Modena Centro Oncologico Modenese, Policlinico Modena, Italy
| | - D Mannina
- Divisione di Ematologia, Ospedale Papardo, Messina, Italy
| | - A G Recchia
- Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| | - A Neri
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - N E Kay
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - M Ferrarini
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - F Morabito
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| |
Collapse
|
7
|
Festini G, Longaro F, Volpe C. [Primary extranodal non-Hodgkin's lymphoma of the head and neck]. Recenti Prog Med 1997; 88:169-72. [PMID: 9206813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Primitive extranodal head and neck non-Hodgkin's lymphoma represents 10% of total non-Hodgkin's Lymphomas and 5% of total head and neck malignant tumors, preferably 55-65 years old males. The aim of this study was to review the literature and to compare the available data with our cases, particularly referring to the results of therapy. We studied 7 cases of primitive extranodal head and neck non-Hodgkin's lymphoma (5 male and 2 females, mean age 58 years) observed between 1989 and 1994. All patients were treated with polychemotherapy, 2 of them with combined therapy. After a mean follow-up of 44 months, 6 patients (85.7%) still are in complete remission. Primary extranodal head and neck non-Hodgkin's lymphomas present peculiar clinical features compared to other lymphomas. The best treatment is the polychemotherapy (including anthracycline) associated (combined) with radiotherapy. A minimal follow-up of 5 years is required, also considering nodal and extranodal relapses not adjacent to the beginning site.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Head and Neck Neoplasms/drug therapy
- Head and Neck Neoplasms/radiotherapy
- Humans
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/radiotherapy
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/radiotherapy
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/radiotherapy
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/radiotherapy
- Male
- Middle Aged
- Time Factors
Collapse
Affiliation(s)
- G Festini
- I Divisione di Medicina Interna, Ambulatorio di Immunologia ed Ematologia, Ospedale Cattinara, Trieste
| | | | | |
Collapse
|
9
|
Abstract
Urography (IVU) is considered the best first investigation in patients with suspected ureteric colic, but recently ultrasonography (US), combined with a plain film of the abdomen (KUB), has been suggested as an alternative. We have undertaken a prospective study to see if this approach can be used in an Emergency Department by radiologists with different amounts of ultrasound experience. Some 180 patients with suspected ureteric colic presenting to the Emergency Department over an 8-month period were studied. They had a plain abdominal film (KUB) and US examination of the kidneys, ureters and bladder following hydration. Some 120 patients subsequently underwent IVU at a mean interval of 3.5 days after the ultrasound examination. Of these, 15 patients passed a stone before their IVU. Of the remaining 105 patients, 44 had an IVU positive for stone and 61 had a negative IVU. Fifty of the 60 patients who did not have an IVU had clinical follow-up and 31 had ultrasound. Our findings in this prospective study suggest that in the hydrated patient the combination of KUB plus US is a sensitive but not very specific screening test (sensitivity 95%, specificity 67%). Because of the high negative predictive value of KUB plus US (95%), urography is not likely to be helpful when KUB plus US are negative. Urography is indicated only if KUB plus US findings are equivocal or if intervention is necessary. If we had used KUB plus US alone as the first test in our patients, urography would have been unnecessary in approximately 60%. Twenty per cent of our patients passed a stone in the first 48 h.
Collapse
Affiliation(s)
- L Dalla Palma
- Institute of Radiology, University of Trieste, Italy
| | | | | | | | | | | |
Collapse
|